HighTower Advisors’s Aprea Therapeutics APRE Stock Holding History

HighTower Advisors’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6K	Hold	13,864	–	–	﹤0.01%	3784
2025 Q4	$11.8K	Hold	13,864	–	–	﹤0.01%	3632
2025 Q3	$20.4K	Hold	13,864	–	–	﹤0.01%	3672
2025 Q2	$23.4K	Hold	13,864	–	–	﹤0.01%	3606
2025 Q1	$28.3K	Hold	13,864	–	–	﹤0.01%	3496
2024 Q4	$45.6K	Hold	13,864	–	–	﹤0.01%	3466
2024 Q3	$38K	Hold	13,864	–	–	﹤0.01%	3439
2024 Q2	$56K	Hold	13,864	–	–	﹤0.01%	3291
2024 Q1	$93K	Buy	+13,864	New	+$86.2K	﹤0.01%	3164

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors's APRE Position: Q1 2026 in Review

HighTower Advisors held its Aprea Therapeutics (APRE) position steady in Q1 2026 at 13,864 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3784.

HighTower Advisors first reported a position in APRE in Q1 2024 and has held it in 9 quarters since. The position peaked at $93K in Q1 2024. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

HighTower Advisors held 13,864 shares of Aprea Therapeutics worth $10.6K as of Q1 2026.
HighTower Advisors left its Aprea Therapeutics share count unchanged in Q1 2026.
Aprea Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3784 holding.
HighTower Advisors first reported a position in Aprea Therapeutics in Q1 2024 and has held it in 9 quarters since.
HighTower Advisors's Aprea Therapeutics position peaked at $93K in Q1 2024.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.